<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Johnson K</submitter><funding>NHGRI NIH HHS</funding><funding>University of North Carolina Wilmington</funding><funding>National Institutes of Health</funding><funding>National Human Genome Research Institute</funding><pagination>262-288</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8900524</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(2)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Understanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.&lt;h4>Methods&lt;/h4>We searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.&lt;h4>Results&lt;/h4>Across the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.&lt;h4>Conclusion&lt;/h4>We describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing.</pubmed_abstract><journal>Genetics in medicine : official journal of the American College of Medical Genetics</journal><pubmed_title>A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders.</pubmed_title><pmcid>PMC8900524</pmcid><funding_grant_id>P50 HG004488</funding_grant_id><funding_grant_id>U01 HG006487</funding_grant_id><funding_grant_id>2P50 HG004488</funding_grant_id><funding_grant_id>2U01 HG006487</funding_grant_id><pubmed_authors>Johnson K</pubmed_authors><pubmed_authors>Lich KH</pubmed_authors><pubmed_authors>Saylor KW</pubmed_authors><pubmed_authors>Guynn I</pubmed_authors><pubmed_authors>Berg JS</pubmed_authors><pubmed_authors>Hicklin K</pubmed_authors></additional><is_claimable>false</is_claimable><name>A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders.</name><description>&lt;h4>Purpose&lt;/h4>Understanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.&lt;h4>Methods&lt;/h4>We searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.&lt;h4>Results&lt;/h4>Across the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.&lt;h4>Conclusion&lt;/h4>We describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2025-04-04T09:10:25.575Z</modification><creation>2025-02-18T23:36:36.347Z</creation></dates><accession>S-EPMC8900524</accession><cross_references><pubmed>34906467</pubmed><doi>10.1016/j.gim.2021.10.008</doi></cross_references></HashMap>